● Recruiting
Phase II
Oncology
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
What is being tested: Subcutaneous zilucoplan, a complement C5 inhibitor, is being evaluated for its pharmacokinetics, safety, tolerability, immunogenicity and clinical activity in pediatric…
30 Jul 2026
NCT06055959